Clinical study of chemotherapy-related cognitive impairment in patients with non-Hodgkin lymphoma

Table 1 Basic information for patients with non-Hodgkin’s lymphoma

Clinical characteristics	Value
Age in yr	47 (43–55)
Sex
Male	49
Female	51
Education in yr	7.5 (6–8)
Ann Arbor stage
II stage	62
III stage	26
IV stage	12

Data are n or n (range).

Table 2 Comparison of cytokine and psychological tests before and after chemotherapy

Parameter	BT group	AT group	t/Z value	P value
MMSE	27 (23.75–29)	27 (23.75–29)	-1.16	0.24
VFT	45.20 ± 15.62	42.30 ± 17.53	2.16	< 0.05
SDMT	24.5 (10.5–36)	22.5 (12–33)	0.69	0.49
CDT	8 (3.5–9.25)	7 (2.5–9)	-2.1	< 0.05
RM	13.5 (9–17)	15 (13–18)	-3.7	< 0.01
PM	12.63 ± 3.61	14.43 ± 4.32	-4.97	< 0.01
ECog-12	1.71 (1.25-2.08)	1.79 (1.42-2.08)	-2.84	< 0.01

Data are n (range) or mean ± standard deviation. AT: After treatment; BT: Before treatment; CDT: Clock Drawing Test; ECog-12: Abbreviated Daily Cognition Scale; PM: Prospective memory; RM: Retrospective memory; SDMT: Symbol Number Pattern Test; VFT: Verbal Fluency Test; MMSE: Brief Psychiatric Examination Scale (Mini-Mental State Examination).